Zheng Xing Xing Ye Ri Bao·2025-10-20 08:27Core Insights - The biopharmaceutical sector experienced a slight increase of 0.14% on October 20, with Iwu Biologics leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Biopharmaceutical Sector Performance - Iwu Biologics (300357) saw a significant rise of 10.07%, closing at 32.90 with a trading volume of 228,200 shares and a transaction value of 737 million [1] - Other notable gainers included Olin Biologics (6168889) with a 4.58% increase, closing at 23.96, and Kangchen Pharmaceutical (603590) with a 4.00% increase, closing at 51.19 [1] - The sector also had some underperformers, such as Novavax (688105) which fell by 3.56%, closing at 21.96 [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 239 million from institutional investors, while retail investors saw a net inflow of 270 million [2] - The data indicates that retail investors are actively buying into the sector despite the overall net outflow from larger institutional players [2] Individual Stock Capital Flow - Iwu Biologics had a net inflow of 23.19 million from institutional investors, while it faced a net outflow of 17.27 million from speculative funds [3] - Notably, Huashan Biologics (002007) had a net inflow of 42.16 million from institutional investors, indicating strong institutional interest [3]